MedPath

GRIFOLS BIOLOGICALS LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:2
Completed:4

Trial Phases

3 Phases

Phase 2:2
Phase 3:2
Phase 4:2

Drug Approvals

27

CANADA:7
PHILIPPINES:5
NMPA:4
+1 more agencies

Drug Approvals

Human Albumin

Product Name
Albutein
Approval Number
国药准字SJ20120044
Approval Date
Oct 26, 2023
NMPA

Human Albumin

Product Name
Albutein
Approval Number
国药准字SJ20130023
Approval Date
Oct 26, 2023
NMPA

Human Albumin

Product Name
Albutein
Approval Number
S20130023
Approval Date
Dec 20, 2019
NMPA

Human Albumin

Product Name
Albutein
Approval Number
S20120044
Approval Date
Dec 20, 2019
NMPA

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (33.3%)
Phase 3
2 (33.3%)
Phase 4
2 (33.3%)

Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B

Phase 2
Completed
Conditions
Hemophilia B
Interventions
First Posted Date
2017-03-27
Last Posted Date
2017-07-25
Lead Sponsor
Grifols Biologicals, LLC
Target Recruit Count
13
Registration Number
NCT03091751
Locations
🇧🇬

Medical University Pleven, Pleven, Bulgaria

🇧🇬

National Center of Haematology, Sofia, Bulgaria

🇧🇬

Medical University, University Hospital "Sveta Marina",, Varna, Bulgaria

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries

Phase 3
Completed
Conditions
Soft Tissue Surgical Bleeding
First Posted Date
2012-11-22
Last Posted Date
2017-02-23
Lead Sponsor
Grifols Biologicals, LLC
Target Recruit Count
327
Registration Number
NCT01731938
Locations
🇺🇸

407, Florence, Alabama, United States

🇺🇸

320, 322, 323, Pasadena, California, United States

🇺🇸

404, Bridgeport, Connecticut, United States

and more 22 locations

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients

Phase 4
Active, not recruiting
Conditions
Von Willebrand Disease
First Posted Date
2007-11-08
Last Posted Date
2023-08-25
Lead Sponsor
Grifols Biologicals, LLC
Target Recruit Count
15
Registration Number
NCT00555555

IGIV Study for Chronic ITP Patients Ages 3-70

Phase 3
Completed
Conditions
Idiopathic Thrombocytopenic Purpura
First Posted Date
2007-08-03
Last Posted Date
2017-06-12
Lead Sponsor
Grifols Biologicals, LLC
Target Recruit Count
64
Registration Number
NCT00511147
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Scottsdale Medical Specialists, Scottsdale, Arizona, United States

🇺🇸

Arizona Oncology Associates, Tucson, Arizona, United States

and more 41 locations

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Phase 4
Completed
Conditions
Severe Hemophilia A
Interventions
First Posted Date
2006-05-10
Last Posted Date
2025-01-16
Lead Sponsor
Grifols Biologicals, LLC
Target Recruit Count
51
Registration Number
NCT00323856
Locations
🇵🇱

Oddzial Chorob Wewnetrznych i Hematologii, Poznan, Szkolna, Poland

🇵🇱

Katedra i Klinika Hematologii Collegium Medicum UJ, Krakow, Poland

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.